Save Product
Product Details
Source
Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) is a mouse monoclonal antibody recombinantly expressed from human 293 cells (HEK293), which provides higher batch consistency and long term security of supply.
Antibody Type
Recombinant Monoclonal
Clone
FMC63
Isotype
Mouse IgG2a, Kappa
Host Species
Mouse
Reactivity
Human
Immunogen
Human prolymphocytic leukaemia cell line JVM3
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Specificity
This product is a specific antibody specifically reacts with CD19 protein.
Application
Flow Cytometry (Detection the expression of CD19 on Human cells).
Recommended Dilution
1:50
Isotype Control
The isotype control is sold separately; please refer to Cat. No. DNP-PM487 for product information.
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4) containing 0.03% ProClin 300 and 0.2% BSA, with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 24 months in lyophilized state;
- -70°C for 12 months after reconstitution.
- 2-8 °C for 12 months after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS
Flow cytometric analysis of HEK293/Human CD19 Stable Cell Line staining with PE-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. FM3-PCFM7) at 1:50 dilution (2 μL of the antibody stock solution corresponds to labeling of 1e6 cells in a final volume of 100 µL), compared with isotype control antibody. PE signal was used to evaluate the binding activity (QC tested).
Protocol
Non-specificity of PE-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (Cat. No. FM3-PCFM7) binding to CD3+ cells present in human PBMC. Human PBMCs were simultaneously stained with FITC-labeled anti-CD3 antibody and PE-Labeled Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a (FMC63) (2 μL of the antibody stock solution corresponds to labeling of 5e5 cells in a final volume of 100 µL), washed and then analyzed with FACS. Both FITC and PE positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
B-lymphocyte antigen CD19
- Category：
- Approved Drugs：
14 Details
- Drugs in Clinical Trials：
435 Details
- Highest Development Stage：
Approved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
